LDS/Medical Tests/OncoTarget™ and OncoTreat™ Test for Cancer Therapy Selection

OncoTarget™ and OncoTreat™ Test for Cancer Therapy Selection

Immunotherapy and precision oncology have advanced significantly, highlighting the importance of personalized cancer therapeutics. Patient-specific tumor profiling allows for optimal drug selection, including FDA-approved immunotherapies and investigational agents.

The OncoTarget™ test uses whole-transcriptome sequencing of tumor tissue to identify aberrantly expressed proteins that may serve as therapeutic targets. It currently profiles 193 proteins, which are targeted by 94 FDA-approved drugs and an additional 239 investigational agents in phase II or III clinical trials. The panel is continuously updated as new drugs and targets are validated.

The OncoTreat™ test evaluates the coordinated activity of 6,293 master regulator (MR) proteins within the tumor. By integrating MR analysis with drug perturbation studies in MR-matched cell line models, OncoTreat prioritizes agents most likely to reverse oncogenic activity in a patient’s tumor. Together, OncoTarget™ and OncoTreat™ provide a comprehensive, functional strategy to guide drug prioritization and clinical trial enrollment for patients with treatment-refractory or relapsed cancers.

  • Supports precision oncology by identifying actionable therapeutic targets
  • Guides the selection of FDA-approved drugs or clinical trial enrollment
  • Provides therapeutic options for patients who have failed standard treatments
A personalized report is generated, identifying aberrant proteins and producing a ranked list of drugs (approved and investigational) with potential therapeutic benefit.

Not applicable

Whole transcriptome sequencing (RNASeq) by VIPER (Virtual Proteomics by Enriched Regulon analysis) algorithm.

Fresh frozen tissue or formalin-fixed paraffin-embedded (FFPE).

Whole blood or white blood cells containing ≥50% nucleated cells.

Stability

FFPE blocks stable for months to years.

Blood

  • Ambient: 3-5 days
  • Refrigerated: 7-14days
Immunohistochemistry (IHC), PD-L1 expression analysis, Genomic sequencing panels (DNA-based).
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login